Test Price
2,800 AEDโ Home Collection Available
ZFYVE26 Gene SPG15 Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Clinical Excellence Guarantee
- Accuracy: 99.9% Diagnostic Sensitivity via ISO-accredited NGS plus Sanger validation.
- Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Post-test tele-clinical interpretation with Consultant Medical Genetics, Lina Osama Zaki Quteineh (DHA ID: 9294403).
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The ZFYVE26 gene next-generation sequencing (NGS) test is a comprehensive molecular analysis designed to identify pathogenic variants causative of Spastic Paraplegia Type 15 (SPG15). This autosomal recessive neurological disorder is characterized by progressive lower extremity spasticity and weakness. Our methodology integrates full-gene NGS sequencing with deletion/duplication analysis and Sanger confirmation to ensure maximal diagnostic yield.
| Feature | DNA Labs UAE NGS Test | Conventional Single-Gene Sanger |
|---|---|---|
| Methodology | NGS full-gene sequencing + deletion/duplication analysis + Sanger confirmation | Sanger sequencing of coding exons only |
| Diagnostic Sensitivity | 99.9% (detects deep intronic & copy-number variants) | ~85%, misses large rearrangements |
| Sample Types | Whole blood, extracted DNA, dried blood spot (FTA card) | Whole blood only |
| Turnaround Time | 21โ28 business days | 14โ21 days (may require costly reflex to NGS) |
| Bioinformatics & Interpretation | ACMG guidelines, population-specific databases, DHA-approved report | Basic mutation scanning, no CNV analysis |
| Pre-Test Genetic Counselling | Mandatory included session; pedigree analysis | Not routinely provided |
Physician Insight & Safety Protocols
โA comprehensive genetic analysis for SPG15 reveals the molecular etiology, guiding prognosis and family planning. The NGS panel approach ensures no pathogenic variant is overlooked, providing definitive diagnosis for complex hereditary spastic paraplegias. Proper pre-test counselling and informed consent are essential components of this diagnostic pathway.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA ID: 9294403)
Clinical Advisory & Best Practice
Advisory: This test is intended for diagnostic confirmation in symptomatic individuals with family history consistent with hereditary spastic paraplegia. It is not a general screening tool. A detailed neurological examination and family pedigree are prerequisites for clinical validity. Results should be correlated with imaging and electrophysiological studies.
Patient Safety Exclusion Criteria
Contraindications & Emergency Red Flags
- Not indicated for asymptomatic minors without a confirmed family mutation and informed consent as per UAE Federal Law No. 2 of 2019.
- Contraindicated in patients with acute neurological decompensation requiring immediate hospitalization.
- Cannot be processed from samples collected in non-DHA-licensed facilities or without a completed consent form.
Emergency Red Flags:
- Sudden severe spasticity or new-onset bowel/bladder dysfunction โ go to the nearest ER.
- Rapid cognitive decline or seizures โ may indicate an alternative diagnosis.
- Unexplained falls with injury; do not wait for test results, seek immediate care.
For any urgent medical concern, call 998 or visit your nearest government hospital.
Patient FAQ & Clinical Guidance
1. What is the ZFYVE26 SPG15 genetic test?
This is a targeted genetic test using Next-Generation Sequencing (NGS) to analyze the ZFYVE26 gene for mutations linked to Spastic Paraplegia Type 15 (SPG15), an inherited neurological condition.
2. Who should consider taking this test?
Individuals presenting with progressive spastic paraplegia of unknown cause, particularly with a family history consistent with autosomal recessive inheritance. It is also appropriate for confirming a clinical suspicion of SPG15 and for reproductive planning in affected families.
3. How is the sample collected, and can it be done at home?
Standard collection involves a whole blood sample, extracted DNA, or a dried blood spot (FTA card). Our VIP Mobile Phlebotomy service allows for a secure, temperature-controlled home collection in any UAE emirate, 8 AM to 11 PM daily.
4. What is the turnaround time and cost of the test?
The total turnaround time is 21 to 28 business days. The test is priced at 2800 AED, inclusive of pre- and post-test genetic counselling with our DHA-licensed genetics team.
5. Is genetic counselling included in the test price?
Yes, mandatory pre-test counselling and a post-result tele-clinical interpretation session with a Consultant Medical Genetics are included. This ensures you fully understand the implications of your results.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: DNA Labs UAE strictly adheres to UAE federal laws governing genetic testing and data privacy.
- Data Protection: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) guarantees the confidentiality and security of your genetic data.
- Health Data Usage: Federal Law No. 2 of 2019 regulates the use of information and communication technology in health fields, ensuring your medical records are handled with the highest integrity.
- Medical Liability: Federal Decree-Law No. 4 of 2016 on Medical Liability protects your rights throughout the diagnostic process, from sample collection to result disclosure.
- DHA Licensing: Our facility operates under DHA License No. 1143, located in Dubai Healthcare City, ensuring all practices meet the UAE's stringent healthcare standards.
Clinical & Logistical Metadata
| Test Name | ZFYVE26 Gene SPG15 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21โ28 Business Days |
| Sample Type / Matrix | Whole Blood, Extracted DNA, Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) + Deletion/Duplication Analysis + Sanger Confirmation |
| ICD-10-CM Code | G11.4 |
| LOINC Code | 101407-3 |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians